ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly baqsimi (nasal glucagon) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)
Latest, Q4 2024
4.30
Period ended Dec 31, 2024
Change on a year earlier
-77.6%
19.2 in Q4 2023
History
12 quarters
Since Q4 2019
Sources
8
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Baqsimi (nasal glucagon) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 31, 2024 | 4.30 | -77.6% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| Q3 2024 | Sep 30, 2024 | 13.4 | +2.3% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 12.4 | -98.0% | Form 10-Q (filed 2024-08-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 19.2 | -49.6% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 13.1 | -69.5% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 614 | +2,016.9% | Form 10-Q (filed 2024-08-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 38.1 | – | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 43 | – | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 29 | – | Form 10-Q (filed 2023-08-08) ↗ |
| Q4 2020 | Dec 31, 2020 | 23.8 | +47.8% | Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗ |
| Q1 2020 | Mar 31, 2020 | 17.8 | – | Earnings Release (Form 8-K FY2020Q1 EX-99.1) (filed 2020-04-23) ↗ |
| Q4 2019 | Dec 31, 2019 | 16.1 | – | Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗ |
Breakdown
What makes up baqsimi (nasal glucagon) — worldwide revenue ($m) [legacy separate disclosure]
Cite this data
StockData. (2026). Eli Lilly Baqsimi (nasal glucagon) — Worldwide revenue ($M) [legacy separate disclosure] ($M), quarterly Q4 2019–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_baqsimi_ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.